Bregvadze T R, Tseluĭko V I, Mishchuk N E
Georgian Med News. 2013 Dec(225):60-7.
Hypertension is the most common disease of the cardiovascular system. Active treatment of hypertension with adequate control of blood pressure (BP) can prevent complications, improve life quality and increase life expectancy. One of the interesting new antihypertensive agents, from the group of angiotensin receptor blockers is olmesartan. The obvious advantages of ambulatory blood pressure monitoring to traditional one-time measurements of BP make this method perspective for quality control of anti-hypertensive therapy. The aim of this study was to evaluate the influence of treatment with olmesartan on ambulatory blood pressure monitoring parameters in patients with hypertension. 38 out-patients with hypertension at the age of 25-84 years (mean 55,3±10,6) were studied. Patients received olmesartan 20 mg daily as monotherapy (20 patients (52,6%)) or in combination with other antihypertensive agents (18 patients (47,4%)). Treatment continued for 6 months. The complex examination included: measurement of office brachial BP, electrocardiography, echocardiography and ambulatory blood pressure monitoring (ABPM). As a result of treatment, office BP and diurnal BP, according to ABPM, significantly decreased; the favorable circadian BP profile dynamics were found: significantly less frequently observed lack of reduction in BP during night (daily index - non-dipper) - 18% vs. 64% (p <0,001), while the number of individuals with normal daily index (dipper) increased significantly - 76% vs. 28% (p <0,001). Also there was determined the significant reduction in daytime and nighttime systolic BP variability - by 1.5 mmHg and 2.1 mmHg, respectively, with the normalization of these parameters at the end of the observation period. The presented results allow conclude, that treatment of hypertensive patients with olmesartan provides significant decline not only in office BP, but also in diurnal BP, normalizes BP of active and passive periods, also - daily index and reduces BP variability.
高血压是心血管系统最常见的疾病。积极治疗高血压并充分控制血压(BP)可预防并发症、提高生活质量并延长预期寿命。奥美沙坦是血管紧张素受体阻滞剂类中一种有趣的新型抗高血压药物。动态血压监测相较于传统的一次性血压测量具有明显优势,使该方法成为抗高血压治疗质量控制的一个有前景的手段。本研究的目的是评估奥美沙坦治疗对高血压患者动态血压监测参数的影响。研究了38例年龄在25 - 84岁(平均55.3±10.6岁)的门诊高血压患者。患者每日接受20 mg奥美沙坦单药治疗(20例患者(52.6%))或与其他抗高血压药物联合治疗(18例患者(47.4%))。治疗持续6个月。综合检查包括:诊室肱动脉血压测量、心电图、超声心动图和动态血压监测(ABPM)。治疗结果显示,根据ABPM,诊室血压和日间血压显著下降;发现了有利的昼夜血压模式动态变化:夜间血压未降低(每日指数 - 非杓型)的情况显著减少,从64%降至18%(p<0.001),而每日指数正常(杓型)的个体数量显著增加,从28%增至76%(p<0.001)。还确定日间和夜间收缩压变异性显著降低,分别降低了1.5 mmHg和2.1 mmHg,在观察期结束时这些参数恢复正常。所呈现的结果表明,用奥美沙坦治疗高血压患者不仅可使诊室血压显著下降,还可使日间血压显著下降,使活动期和静息期血压正常化,同时使每日指数正常化并降低血压变异性。